ABSTRACT
The use of electroporation for delivery of chemotherapy is now quite widely used and in further development. Electrochemotherapy is in routine use for cutaneous tumors in more than 100 cancer centers, and several thousand patients have been treated. The term genetic therapy has been coined to describe therapy using different nucleotide formulations, and indeed there are a number of possibilities and more on the way in classic gene therapy; utilizing DNA, a transgene is transferred to cells that may then produce a protein with a medicinal effect. Chronic disease, such as hemophilia, may also be amenable to gene therapy, and here electroporation-based delivery may be of interest as this can be done in an immunologically safe way so that antibodies against the transgene product may be avoided. In a number of diseases, such as hemophilia, correcting a fraction of the anomaly caused by the genetic defect may be sufficient to cause a real difference for the patient.
